My analysis: this was after only 12 weeks of treatment.
My analysis: this was after only 12 weeks of treatment. They said that it was after 8 weeks that they noticed improvement. So, the rate of response may go up when people are treated longer.
Also, it looks like higher doses should be tried too. Again, CTIX was being cautious with the dosing regimen. The horrible example of the French test in which 5 people were badly injured and one was killed outright, should show people why caution is smart.
I wonder if it's body-weight dependent? Some drugs are.
Also note that it helped people who previously had been UNSUCCESSFULLY treated by biologics and other drugs.
So it looks promising. We won't know if it can help everyone until more testing, over a longer period of time, can happen, but the advantages of trying an ORAL medication (no needles) as the first line of treatment before getting into needles and more side effects seems pretty obvious.
4
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...
Continue Reading
Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...
Continue Reading
A Bumpy Ride Towards Future of Commercial Vehicles In the midst of a bustling Hannover, CDTL, that plucky contender in e-drive systems, is making noise at IAA Transportation 2026. Now, if there's one thing I've learned watching this circus we call the auto industry, it's that innovation rarely strolls in with a polite knock. It barges through the door, often leaving a...
Continue Reading
Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...
Continue Reading
Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....
Continue Reading
DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...
Continue Reading
Finding Balance in a Chaotic World Forget the market roller coaster for a second. Let's chat about something else that often feels like a roller coaster—life itself. Dr. Karl D. Liedtka's book, "Be Present, LIVE Fully," dives into that hot mess and offers a way to get a grip on your own sanity. This isn't just another self-help book filled with empty platitudes; it's...
Continue Reading
New Leadership Steers Strategic Growth Just when you thought the subscription game couldn't get more interesting, in steps Janesh Janardhanan. Frost & Sullivan, the big brain of analytics and growth advice, has handed him the reins of their fancy subscriptions portfolio. Janardhanan's job? To pump some muscle into their global growth and ensure their analytics and...
Continue Reading
Breaking New Ground with EXCiPACT Certification Here's a tale unfolding in the high-stakes world of biotechnology—CelluPro, a standout in cell culture media, just snagged the EXCiPACT™ certification. This isn't just some fancy plaque for the wall. It's a stamp of approval that screams reliability in the global biomanufacturing supply scene. Why This Certification...
Continue Reading
New Payment Option Brings Flexibility Seems like Six Flags isn't just about roller coasters anymore—now they're playing the long game with wallet-friendly options. Flex Pay by Upgrade is the latest spin on season pass financing, letting guests divvy up payments and kickstart their amusement park fun right away. This move could be a game-changer for folks looking to lock...
Continue Reading
Top 5 Most Recently Viewed Articles
The Growing Recycling Equipment Market The Recycling Equipment Market is on a remarkable trajectory, with expectations to soar from USD 29.46 billion in 2023 to USD 48.07 billion by 2032. This promising growth reflects a compound annual growth rate (CAGR) of 5.59% between 2024 and 2032. A global awakening to environmental issues is driving industries and governments alike...
Continue Reading
Callinex Mines Receives Exploration Permit for Point Leamington Project Callinex Mines Inc., a prominent player in the base and precious metals sector, has recently secured a two-year exploration permit for its Pt. Leamington Project. This exciting development comes as the company aims to enhance its mineral resource base, specifically targeting the rich deposits of gold,...
Continue Reading
Oncology Approvals and Their Impact The landscape of oncology treatment is undergoing a remarkable transformation. Regulatory bodies like the FDA are not only approving new drugs but actively reshaping the future of cancer therapies. Recently, we've witnessed a surge in approvals, with over 50 new oncology treatments being authorized, signifying a pivotal change in...
Continue Reading
Oportun's Latest $425 Million Financing Success Oportun has recently achieved a significant milestone by successfully issuing $425 million in asset-backed securities. This accomplishment highlights the company's continual growth and robust position in the financial services sector. Understanding the Transaction This transaction comprised revolving fixed-rate notes backed...
Continue Reading
Significant Drop in CEO Confidence in Recent Survey The Conference Board recently reported a dramatic decline in the Measure of CEO Confidence, reflecting a stark shift in the sentiment among business leaders. In Q2 2025, the metric plunged by 26 points to a mere 34, marking the lowest level since late 2022. This decline is notable as it represents the most significant...
Continue Reading